Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
10
03
2022
accepted:
03
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
11
8
2022
Statut:
epublish
Résumé
There is no report on the long-term outcomes of ataxia with antibodies against Delta and Notch-like epidermal growth factor-related (DNER). We aimed to describe the clinical-immunologic features and long-term outcomes of patients with anti-DNER antibodies. Patients tested positive for anti-DNER antibodies between 2000 and 2020 were identified retrospectively. In those with available samples, immunoglobulin G (IgG) subclass analysis, longitudinal cerebellum volumetry, human leukocyte antigen isotyping, and CSF proteomic analysis were performed. Rodent brain membrane fractionation and organotypic cerebellar slices were used to study DNER cell-surface expression and human IgG binding to the Purkinje cell surface. Twenty-eight patients were included (median age, 52 years, range 19-81): 23 of 28 (82.1%) were male and 23 of 28 (82.1%) had a hematologic malignancy. Most patients (27/28, 96.4%) had cerebellar ataxia; 16 of 28 (57.1%) had noncerebellar symptoms (cognitive impairment, neuropathy, and/or seizures), and 27 of 28 (96.4%) became moderately to severely disabled. Half of the patients (50%) improved, and 32.1% (9/28) had no or slight disability at the last visit (median, 26 months; range, 3-238). Good outcome significantly associated with younger age, milder clinical presentations, and less decrease of cerebellar gray matter volumes at follow-up. No human leukocyte antigen association was identified. Inflammation-related proteins were overexpressed in the patients' CSF. In the rodent brain, DNER was enriched in plasma membrane fractions. Patients' anti-DNER antibodies were predominantly IgG1/3 and bound live Purkinje cells in vitro. DNER ataxia is a treatable condition in which nearly a third of patients have a favorable outcome. DNER antibodies bind to the surface of Purkinje cells and are therefore potentially pathogenic, supporting the use of B-cell-targeting treatments.
Sections du résumé
BACKGROUND AND OBJECTIVES
There is no report on the long-term outcomes of ataxia with antibodies against Delta and Notch-like epidermal growth factor-related (DNER). We aimed to describe the clinical-immunologic features and long-term outcomes of patients with anti-DNER antibodies.
METHODS
Patients tested positive for anti-DNER antibodies between 2000 and 2020 were identified retrospectively. In those with available samples, immunoglobulin G (IgG) subclass analysis, longitudinal cerebellum volumetry, human leukocyte antigen isotyping, and CSF proteomic analysis were performed. Rodent brain membrane fractionation and organotypic cerebellar slices were used to study DNER cell-surface expression and human IgG binding to the Purkinje cell surface.
RESULTS
Twenty-eight patients were included (median age, 52 years, range 19-81): 23 of 28 (82.1%) were male and 23 of 28 (82.1%) had a hematologic malignancy. Most patients (27/28, 96.4%) had cerebellar ataxia; 16 of 28 (57.1%) had noncerebellar symptoms (cognitive impairment, neuropathy, and/or seizures), and 27 of 28 (96.4%) became moderately to severely disabled. Half of the patients (50%) improved, and 32.1% (9/28) had no or slight disability at the last visit (median, 26 months; range, 3-238). Good outcome significantly associated with younger age, milder clinical presentations, and less decrease of cerebellar gray matter volumes at follow-up. No human leukocyte antigen association was identified. Inflammation-related proteins were overexpressed in the patients' CSF. In the rodent brain, DNER was enriched in plasma membrane fractions. Patients' anti-DNER antibodies were predominantly IgG1/3 and bound live Purkinje cells in vitro.
DISCUSSION
DNER ataxia is a treatable condition in which nearly a third of patients have a favorable outcome. DNER antibodies bind to the surface of Purkinje cells and are therefore potentially pathogenic, supporting the use of B-cell-targeting treatments.
Identifiants
pubmed: 35940913
pii: 9/5/e200018
doi: 10.1212/NXI.0000000000200018
pmc: PMC9359625
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Nerve Tissue Proteins
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
pubmed: 10860804
J Clin Oncol. 1997 Aug;15(8):2866-72
pubmed: 9256130
JAMA Neurol. 2014 Aug;71(8):1003-8
pubmed: 24935874
Arch Neurol. 1976 Sep;33(9):660-1
pubmed: 962649
J Neuroimmunol. 2001 Mar 1;114(1-2):259-64
pubmed: 11240040
J Neurol Sci. 2001 Mar 1;184(2):131-7
pubmed: 11239946
Ann Neurol. 2003 Mar;53(3):325-36
pubmed: 12601700
Ann Neurol. 2012 Jun;71(6):815-24
pubmed: 22447725
J Leukoc Biol. 2004 Feb;75(2):163-89
pubmed: 14525967
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3):
pubmed: 32170042
PLoS One. 2016 Aug 30;11(8):e0161656
pubmed: 27575749
Brain. 2021 Oct 22;144(9):2709-2721
pubmed: 33843981
Neurology. 2000 Sep 12;55(5):713-5
pubmed: 10980743
Neurology. 2020 Dec 1;95(22):e3012-e3025
pubmed: 32928978
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Cerebellum. 2016 Apr;15(2):213-32
pubmed: 25823827
Neuroimage. 2017 Feb 15;147:916-924
pubmed: 27833012
Brain. 2003 Jun;126(Pt 6):1409-18
pubmed: 12764061
Auto Immun Highlights. 2020 Jan 22;11(1):2
pubmed: 32127039
Front Immunol. 2019 Sep 06;10:1990
pubmed: 31555262
Ann Neurol. 2003 Jan;53(1):21-8
pubmed: 12509844
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Neurol Sci. 2001 Mar 1;184(2):101-22
pubmed: 11239944
Nat Neurosci. 2005 Jul;8(7):873-80
pubmed: 15965470
Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):e124-e127
pubmed: 34782261
JAMA Neurol. 2016 Sep 1;73(9):1115-24
pubmed: 27428927
Brain. 2001 Jun;124(Pt 6):1138-48
pubmed: 11353730
Neurology. 2003 Jan 28;60(2):230-4
pubmed: 12552036
J Neuroimmunol. 2014 Feb 15;267(1-2):102-4
pubmed: 24439423
J Neuroimmunol. 1997 Apr;74(1-2):55-61
pubmed: 9119979
Blood Adv. 2020 Jun 9;4(11):2548-2555
pubmed: 32516414
Acta Neuropathol. 1998 Jul;96(1):1-7
pubmed: 9678507
Acta Neuropathol. 2018 Apr;135(4):569-579
pubmed: 29299667
J Biol Chem. 2002 Jul 12;277(28):25400-7
pubmed: 11950833
Brain. 2018 Jan 1;141(1):248-270
pubmed: 29206893
J Clin Immunol. 2012 Oct;32(5):1007-11
pubmed: 22644841